Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that it has received confirmation from the U.S. FDA that the New Drug Application (NDA) for Intermezzo (zolpidem tartrate sublingual lozenge) has been accepted for review by the agency.
The details can be read here.
No comments:
Post a Comment